Commitments and Contingencies (Details) $ / shares in Units, $ in Thousands					1 Months Ended	12 Months Ended
	Mar. 27, 2024 USD ($)	Oct. 27, 2023 USD ($)	Feb. 03, 2020 USD ($) milestone	Sep. 24, 2018 USD ($) therapy milestone	Jul. 31, 2019 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2019 unit $ / shares	Aug. 14, 2023 USD ($)	Jun. 22, 2021 USD ($)	Jun. 09, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)
Loss Contingencies [Line Items]
Accrued expenses and other current liabilities						$ 4,172	$ 13,214
Total revenues, net						1,924	18,051
Royalty agreement, payment received					$ 2,000
Period after public launch to terminate agreement					3 years
Buyout option, percentage of net present value of royalty payments					75.00%
Aevi
Loss Contingencies [Line Items]
Payment for contingent consideration						0
Aevi
Loss Contingencies [Line Items]
Number of contingent consideration milestones | milestone			2
Contingent consideration			$ 6,500
Ichorion
Loss Contingencies [Line Items]
Contingent consideration				$ 15,000
Payment for contingent consideration						0
Number of contingent consideration milestones | milestone				3
AlmataBio Transaction | Subsequent Event
Loss Contingencies [Line Items]
Payment to acquire business	$ 7,500
License and other revenue
Loss Contingencies [Line Items]
Total revenues, net						516	14,687
CERC-801, CERC-802, And CERC-803 | Ichorion
Loss Contingencies [Line Items]
Number of preclinical therapies | therapy				3
CERC-913 | Ichorion
Loss Contingencies [Line Items]
Number of preclinical therapies | therapy				1
Milestone One | Aevi
Loss Contingencies [Line Items]
Contingent consideration			2,000
Milestone One | Ichorion
Loss Contingencies [Line Items]
Payment for contingent consideration				$ 6,000
Milestone One | AlmataBio Transaction | Subsequent Event
Loss Contingencies [Line Items]
Contingent consideration	5,000
Milestone Two | Aevi
Loss Contingencies [Line Items]
Contingent consideration			$ 4,500
Milestone Two | Ichorion
Loss Contingencies [Line Items]
Payment for contingent consideration				5,000
Milestone Two | AlmataBio Transaction | Subsequent Event
Loss Contingencies [Line Items]
Contingent consideration	$ 15,000
Milestone Three | Ichorion
Loss Contingencies [Line Items]
Payment for contingent consideration				$ 4,000			0
Lilly License Agreement | AVTX-009 Lilly License Agreement
Loss Contingencies [Line Items]
Collaborative arrangement, rights and obligations, milestone payments						70,000
Lilly License Agreement | AVTX-009 Lilly License Agreement | Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment						720,000
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement
Loss Contingencies [Line Items]
Upfront license fee													$ 10,000
Percent of payments received from sublicensing													30.00%
Research and development						0
Cumulative expense recognized to date						0
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment													$ 112,500
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two
Loss Contingencies [Line Items]
Maximum aggregate milestone payment													$ 75,000
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement
Loss Contingencies [Line Items]
Upfront license fee										$ 400
Research and development						0
Patent costs										500
Cumulative expense recognized to date						0
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment										24,200
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two
Loss Contingencies [Line Items]
Maximum aggregate milestone payment										$ 50,000
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement
Loss Contingencies [Line Items]
Maximum aggregate milestone payment						5,500
Upfront license fee						500
Research and development						0
Cumulative expense recognized to date						500
Alto | AVTX-301 Out-License
Loss Contingencies [Line Items]
Maximum proceeds from milestones												$ 18,600
Revenue recognized from milestones to date							0
ES | AVTX-406 License Assignment
Loss Contingencies [Line Items]
Revenue recognized from milestones to date							$ 0
ES | Milestone One | AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones											$ 6,000
ES | Milestone Two | AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones											$ 20,000
AUG Therapeutics, LLC | Purchase Agreement
Loss Contingencies [Line Items]
Upfront payment paid		$ 200
Asset acquisition consideration transferred, liabilities		$ 400
Contingent milestone upfront payment percentage		0.20
Contingent milestone payment		$ 15,000
Maximum potential payments		45,000
AUG Therapeutics, LLC | Purchase Agreement | AVTX-800 Series Asset Sale
Loss Contingencies [Line Items]
Upfront payment paid		200
Asset acquisition consideration transferred, liabilities		$ 400
Contingent milestone upfront payment percentage		0.20
Contingent milestone payment		$ 15,000
Maximum potential payments		$ 45,000
AUG Therapeutics, LLC | Purchase Agreement | License and other revenue
Loss Contingencies [Line Items]
Total revenues, net						500
TRIS Pharma | Karbinal Agreement
Loss Contingencies [Line Items]
Minimum quantity required | unit								70,000
Make whole payment per unit (in dollars per share) | $ / shares								$ 30
Apollo AP43 Limited
Loss Contingencies [Line Items]
Estimate of possible loss									$ 800
Accrued expenses and other current liabilities						$ 200